Last reviewed · How we verify
Ticagrelor- Delayed Administration
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation to prevent thrombotic events.
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) with delayed loading dose administration, Prevention of stent thrombosis in percutaneous coronary intervention (PCI).
At a glance
| Generic name | Ticagrelor- Delayed Administration |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | P2Y12 platelet receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, blocking platelet activation and aggregation. This mechanism reduces the formation of blood clots and is used to prevent stent thrombosis and recurrent cardiovascular events. The delayed administration strategy refers to a dosing regimen approach rather than a mechanistic modification of the drug itself.
Approved indications
- Acute coronary syndrome (ACS) with delayed loading dose administration
- Prevention of stent thrombosis in percutaneous coronary intervention (PCI)
Common side effects
- Bleeding
- Bradycardia
- Dyspnea
- Ventricular pauses
Key clinical trials
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor- Delayed Administration CI brief — competitive landscape report
- Ticagrelor- Delayed Administration updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI